Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | ITGB2 | P05107 | 7/20 | 0.58 |
| ▸ | ICAM1 | P05362 | 7/20 | 0.58 |
| ▸ | ITGAL | P20701 | 7/20 | 0.58 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.58 |
| ▸ | FPR2 | P25090 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 2/20 | 0.52 |
| ▸ | MMP9 | P14780 | 3/20 | 0.49 |
| ▸ | MMP2 | P08253 | 2/20 | 0.49 |
| ▸ | ACE | P12821 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5579691 | 1.00 | KMT2A (0.63) | KMT2AITGB2ICAM1ITGALDNMT1 | |
| SCHEMBL1229970 | 0.89 | DNMT1 (0.72) | KMT2AITGB2ICAM1ITGALDNMT1 | |
| SCHEMBL1230163 | 0.89 | DNMT1 (0.72) | KMT2AITGB2ICAM1ITGALDNMT1 | |
| SCHEMBL1653793 | 0.82 | KMT2A (0.68) | KMT2AITGB2ICAM1ITGALDNMT1 | |
| SCHEMBL13554692 | 0.81 | KMT2A (0.73) | KMT2AITGB2ICAM1ITGALDNMT1 | |
| SCHEMBL23174994 | 0.80 | KMT2A (0.62) | KMT2AITGB2ICAM1ITGALDNMT1 | |
| SCHEMBL14398100 | 0.80 | ITGB2 (0.61) | KMT2AITGB2ICAM1ITGALDNMT1 | |
| SCHEMBL7054118 | 0.78 | ALOX15 (0.64) | KMT2AITGB2ICAM1ITGALFPR2 | |
| SCHEMBL2243473 | 0.77 | MEN1 (0.72) | KMT2ACDK2 | |
| SCHEMBL18061117 | 0.77 | FPR2 (0.71) | KMT2AITGB2ICAM1ITGALFPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155730-A1 | Benzodiazepine And Benzopiperazine Analog Inhibitors Of Histone Deacetylase | METHYLGENE, INC. (CA) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155730-A1 | Benzodiazepine And Benzopiperazine Analog Inhibitors Of Histone Deacetylase | HDAC5, HDAC4, HDAC3 | KMT2A 111/4885ITGB2 2269/4885ICAM1 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.